Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$3.11
$3.22
$1.98
$3.60
$29.23M1.5222,722 shs12,261 shs
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
$0.79
+6.3%
$0.73
$0.61
$17.19
$127.78M2.961.51 million shs621,190 shs
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
$7.90
-0.1%
$3.04
$1.31
$7.95
$368.71M1.9663,018 shs864,649 shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.40
-3.1%
$0.40
$0.29
$1.07
$92.20M1.272.45 million shs1.89 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
0.00%0.00%0.00%-7.72%+7.61%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-0.64%+6.16%-4.26%-48.03%-92.34%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-0.25%+0.38%+187.64%+233.76%+169.05%
Vaxart, Inc. stock logo
VXRT
Vaxart
-6.67%-8.87%-6.60%-10.64%-49.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
3.1088 of 5 stars
4.10.00.00.03.42.51.3
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
3.1884 of 5 stars
4.03.00.00.02.32.50.6
Vaxart, Inc. stock logo
VXRT
Vaxart
1.9211 of 5 stars
3.51.00.00.02.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$10.00221.54% Upside
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.22
Hold$9.291,075.41% Upside
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
2.00
Hold$10.8036.71% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00642.57% Upside

Current Analyst Ratings Breakdown

Latest ACST, VIGL, VXRT, and NMRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$11.00 ➝ $8.00
5/27/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$14.00 ➝ $8.00
5/23/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Neutral$8.00
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform
5/22/2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.00
5/13/2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$6.57 per shareN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/A$3.07 per shareN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/A$3.24 per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$47.40M1.95N/AN/A$0.38 per share1.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$12.85M-$1.44N/AN/AN/AN/A-13.61%-11.56%N/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$235.93M-$1.61N/AN/AN/AN/A-73.63%-68.97%8/5/2025 (Estimated)
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$82.46M-$0.27N/AN/AN/A-431.61%-110.46%-62.78%8/14/2025 (Estimated)

Latest ACST, VIGL, VXRT, and NMRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/12/2025Q1 2025
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$0.40-$0.42-$0.02-$0.42N/AN/A
5/7/2025Q1 2025
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.53-$0.49+$0.04-$0.49N/AN/A
3/20/2025Q4 2024
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 million
3/13/2025Q4 2024
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
-$0.49-$0.57-$0.08-$0.57N/AN/A
3/6/2025Q4 2024
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$0.46-$0.37+$0.09-$0.37N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/AN/A
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
7.86
7.86
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/A
10.98
10.98
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
N/A
3.72
3.72
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.83
0.83

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
47.65%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
83.64%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
26.80%
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
18.01%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.77 millionNot Optionable
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
108161.75 million118.91 millionOptionable
Vigil Neuroscience, Inc. stock logo
VIGL
Vigil Neuroscience
4046.67 million27.38 millionNot Optionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.22 million221.57 millionOptionable

Recent News About These Companies

B. Riley Comments on Vaxart's Q3 Earnings (NASDAQ:VXRT)
Vaxart, Inc. stock logo
B. Riley Has Positive Forecast for Vaxart Q3 Earnings
FY2029 Earnings Estimate for Vaxart Issued By B. Riley
Vaxart (NASDAQ:VXRT) Raised to Hold at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acasti Pharma stock logo

Acasti Pharma NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Neumora Therapeutics stock logo

Neumora Therapeutics NASDAQ:NMRA

$0.79 +0.05 (+6.31%)
As of 04:00 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Vigil Neuroscience stock logo

Vigil Neuroscience NASDAQ:VIGL

$7.90 -0.01 (-0.13%)
As of 04:00 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.40 -0.01 (-3.07%)
As of 04:00 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.